Fc gamma RIII (CD16) Antibody (MEM-154) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NB500-378
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow (Cell Surface), Flow Cytometry, Immunoprecipitation, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # MEM-154
Format
BSA Free
Concentration
1.0 mg/ml
Product Specifications
Immunogen
Human granulocytes
Specificity
The antibody MEM-154 reacts with an epitope on CD16 antigen that is residing in proximity to FG loop (probably BC or C'E loop). CD16 is a low affinity receptor for aggregated IgG (FcgammaRIII antigen). The antibody MEM-154 reacts with CD16+ granulocytes. HLDA V; WS Code M MA068 HLDA V; WS Code NK NK51
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Scientific Data Images for Fc gamma RIII (CD16) Antibody (MEM-154) - BSA Free
Flow Cytometry: Fc gamma RIII (CD16) Antibody (MEM-154) - BSA Free [NB500-378]
Flow Cytometry: Fc gamma RIII (CD16) Antibody (MEM-154) [NB500-378] - Separation of FasL transfected L5178Y cells stained using anti-human CD178 (NOK-1) purified antibody (concentration in sample 9 ug/ml, GAM APC, red-filled) from FasL transfected L5178Y cells unstained by primary antibody (GAM APC, black-dashed) in flow cytometry analysis (surface staining).Flow Cytometry: Fc gamma RIII (CD16) Antibody (MEM-154) - BSA Free [NB500-378]
Flow Cytometry: Fc gamma RIII (CD16) Antibody (MEM-154) [NB500-378] - Flow cytometry surface staining pattern of human peripheral blood stained using Fc gamma RIII (CD16) Antibody (MEM-154) purified antibody (concentration in sample 2 ug/ml) GAM APC.Flow Cytometry: Fc gamma RIII (CD16) Antibody (MEM-154) - BSA Free [NB500-378] -
Flow Cytometry: Fc gamma RIII (CD16) Antibody (MEM-154) - BSA Free [NB500-378] - Staining of human peripheral blood cells with anti-human CD16 (MEM-154) purified, GAM/APC.Applications for Fc gamma RIII (CD16) Antibody (MEM-154) - BSA Free
Application
Recommended Usage
Flow Cytometry
5-10 ug/ml
Immunoprecipitation
1:50
Western Blot
1:1000
Application Notes
Flow Cytometry - The antibody MEM-154 does not react with CD16a present on NK cells in many subjects. Immunoprecipitation Western Blot - Non-reducing conditions. Functional Application - The antibody MEM-154 blocks binding of human IgG to FcgammaRIII. This antibody is CyTOF ready.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS (pH 7.4)
Format
BSA Free
Preservative
0.9% Sodium Azide
Concentration
1.0 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C. Do not freeze.
Background: Fc gamma RIII (CD16)
Fc gamma RIIIA/CD16a is expressed as a transmembrane protein on NK cells and on a subset of monocytes, macrophages, CD4+T cells, basophils, and mast cells (1-3). Fc gamma RIIIB/CD16b is primarily expressed on neutrophils as a glycosylphosphatidylinositol (GPI)-anchored protein but is also expressed on a subset of basophils and can be induced on eosinophils (1-3). The soluble form of CD16 (sCD16) which is often produced following exposure to inflammatory signals and protein shedding via metalloproteinases (3). Reduced sCD16 levels have been found in patients with multiple myeloma (3).
Activating NK cell receptor function has been harnessed for its potential in tumor immunotherapy (6). One immunotherapy strategy is using bi- and tri-specific NK cell engagers (BiKE and TriKE) to target the Fc gamma RIIIA/CD16a receptor with tumor-associated antigens to stimulate a cytotoxic response and mount an attack on tumor cells (6). CD16a is also capable of antibody dependent cellular cytotoxicity (ADCC) through recognition of antibodies bound to target cells (6-7). CD16-induced NK cell activation allows for NK co-receptor expression including stimulatory receptors like CD137 or inhibitory receptors like TIGIT and PD-1, which serve as additional regulatory checkpoints during ADCC (7). Therapeutic antibodies for cancer treatment like rituximab or trastuzumab can be recognized by Fc gamma RIIIA/CD16a to activate NK cell-mediated killing of tumor cells (6-7).
References
1. Fossati, G., Bucknall, R. C., & Edwards, S. W. (2001). Fcgamma receptors in autoimmune diseases. European Journal of Clinical Investigation, 31(9), 821-831. https://doi.org/10.1046/j.1365-2362.2001.00881.x
2. Patel, K. R., Roberts, J. T., & Barb, A. W. (2019). Multiple Variables at the Leukocyte Cell Surface Impact Fc gamma Receptor-Dependent Mechanisms. Frontiers in Immunology, 10, 223. https://doi.org/10.3389/fimmu.2019.00223
3. Moldovan, I., Galon, J., Maridonneau-Parini, I., Roman Roman, S., Mathiot, C., Fridman, W. H., & Sautes-Fridman, C. (1999). Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. Immunology Letters, 68(1), 125-134. https://doi.org/10.1016/s0165-2478(99)00041-3
4. Uniprot (P08637)
5. Uniprot (O75015)
6. Sivori, S., Pende, D., Quatrini, L., Pietra, G., Della Chiesa, M., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., & Moretta, L. (2021). NK cells and ILCs in tumor immunotherapy. Molecular Aspects of Medicine, 80, 100870. https://doi.org/10.1016/j.mam.2020.100870
7. Muntasell, A., Ochoa, M. C., Cordeiro, L., Berraondo, P., Lopez-Diaz de Cerio, A., Cabo, M., Lopez-Botet, M., & Melero, I. (2017). Targeting NK-cell checkpoints for cancer immunotherapy. Current Opinion in Immunology, 45, 73-81. https://doi.org/10.1016/j.coi.2017.01.003
Long Name
Fc gamma Receptor III
Alternate Names
FcgRIII
Entrez Gene IDs
2214 (Human)
Gene Symbol
FCGR3A
UniProt
Additional Fc gamma RIII (CD16) Products
Product Documents for Fc gamma RIII (CD16) Antibody (MEM-154) - BSA Free
Product Specific Notices for Fc gamma RIII (CD16) Antibody (MEM-154) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...